US-based medical technology company Haemonetics has reached an agreement to sell the wholly owned subsidiary Inlog Holdings France to French private equity company Abénex.

Inlog Holdings France develops and sells blood bank and hospital software solutions through its subsidiary In Log. The products are used mainly in France and in several other countries outside of the US.

Haemonetics president and CEO Chris Simon said: “This divestiture and the recent sale of our US blood donor software help shift our portfolio toward our growth segments. Software that supports our growth and sector leadership remains an important part of our innovation agenda.”

As part of the transaction, Abénex will acquire Haemonetics’ ownership interest in Inlog Holdings France and In Log. This covers the ownership transfer of products, including the EdgeSuite software solutions such as EdgeBlood, EdgeCell, EdgeTrack and EdgeLab, and SapaNet software solution.

These products are designed to suit the operational needs of blood banks and blood centres. They optimise workflow efficiencies in hospital labs to increase patient safety and streamline lab processes.

Abénex director Thomas Peretti said: “We are enthusiastic about continuing what Haemonetics and the Inlog team have achieved over the last decade.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We will rely on Inlog’s team to better serve its clients by investing in innovation and in people. We are convinced that Inlog has strong assets to grow within the European market.”

Subject to customary closing conditions, the transaction is expected to close in the third quarter of this year.

Last month, Haemonetics announced the sale of its Fajardo, Puerto Rico, manufacturing operations to GVS.

In May, the company entered a definitive agreement to sell certain blood donor management software solution assets within its Blood Center business unit to the GPI Group.